Sargent Investment Group LLC Sells 377,384 Shares of Cytosorbents Co. (NASDAQ:CTSO)

Sargent Investment Group LLC decreased its holdings in Cytosorbents Co. (NASDAQ:CTSO) by 23.2% during the 4th quarter, HoldingsChannel reports. The firm owned 1,248,863 shares of the medical research company’s stock after selling 377,384 shares during the quarter. Sargent Investment Group LLC’s holdings in Cytosorbents were worth $1,136,000 at the end of the most recent reporting period.

Separately, Geode Capital Management LLC grew its holdings in shares of Cytosorbents by 7.5% in the third quarter. Geode Capital Management LLC now owns 467,058 shares of the medical research company’s stock valued at $701,000 after acquiring an additional 32,415 shares in the last quarter. 32.87% of the stock is owned by hedge funds and other institutional investors.

Cytosorbents Stock Performance

Shares of NASDAQ:CTSO opened at $0.99 on Wednesday. The firm has a market cap of $54.04 million, a PE ratio of -2.75 and a beta of 0.61. The firm’s 50 day simple moving average is $0.96 and its 200-day simple moving average is $1.04. The company has a debt-to-equity ratio of 1.06, a quick ratio of 1.58 and a current ratio of 1.97. Cytosorbents Co. has a one year low of $0.70 and a one year high of $1.59.

Cytosorbents (NASDAQ:CTSO) last posted its quarterly earnings data on Thursday, November 7th. The medical research company reported ($0.09) EPS for the quarter, missing the consensus estimate of ($0.06) by ($0.03). Cytosorbents had a negative return on equity of 118.54% and a negative net margin of 49.47%. The company had revenue of $9.39 million for the quarter, compared to analyst estimates of $10.14 million. During the same quarter in the previous year, the firm posted ($0.21) earnings per share. As a group, equities analysts predict that Cytosorbents Co. will post -0.3 EPS for the current year.

Wall Street Analyst Weigh In

A number of analysts recently commented on CTSO shares. StockNews.com initiated coverage on Cytosorbents in a research report on Wednesday, January 29th. They set a “hold” rating for the company. HC Wainwright reiterated a “neutral” rating and issued a $1.00 price objective on shares of Cytosorbents in a report on Monday, November 11th. Finally, D. Boral Capital reaffirmed a “buy” rating and set a $10.00 price objective on shares of Cytosorbents in a research report on Monday, January 13th. Two investment analysts have rated the stock with a hold rating, two have issued a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $4.67.

Cytosorbents Company Profile

Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology in the United States, Germany, and internationally. Its flagship product is CytoSorb, an extracorporeal cytokine adsorber for adjunctive therapy in the treatment of sepsis, adjunctive therapy in other critical care applications, prevention, and treatment of perioperative complications, and maintaining or enhancing the quality of solid organs harvested from donors for organ transplant; and offers VetResQ, a device for adjunctive therapy in the treatment of sepsis, pancreatitis, and other critical illnesses in animals.